Head-to-head · free
The Precision Peptide Company vs Starbucks
PNGAF vs SBUX — return on capital, cash generation, margins and balance sheet side by side.
PNGAF
0 / 0
measures where PNGAF leads
SBUX
0 / 0
measures where SBUX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | PNGAF | SBUX · FY2026 |
|---|---|---|
| Revenue | — | $37.9B |
| Net income | — | $2.5B |
| Revenue growth (yearly, multi-year) | — | 4.1% |
| Free cash flow | — | $3.7B |
| Free cash flow margin | — | 9.8% |
| Net cash / (debt) | — | — |
| ROIC | — | 11.6% |
| Return on equity | — | — |
| Gross margin | — | 22.8% |
| Operating margin | — | 9.6% |
| Net debt / EBITDA | — | 2.73x |
Figures are as reported by each company; latest fiscal year shown.
Where Starbucks's cash went (FY2026)
- Capital spending
- $1.3B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free